A prospective, open-label, single centre study of RBX 2660 for prevention of relapse of infections

Trial Profile

A prospective, open-label, single centre study of RBX 2660 for prevention of relapse of infections

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2016

At a glance

  • Drugs RBX 2660 (Primary)
  • Indications Bacterial infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Jan 2016 New trial record
    • 11 Jan 2016 According to a Rebiotix media release, first patient has been treated in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top